Pilot study of an association between a common variant in the non-muscle myosin heavy chain 9 (MYH9) gene and type 2 diabetic nephropathy in a Taiwanese population

Application of Clinical Genetics

Volumn 3, Issue , 2010, Pages 17-22

  Hsieh, Chang Hsun ^a   Hung, Yi Jen ^a   Pei, Dee ^b   Kuo, Shi Wen ^c   Lin, Eugene ^d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d VITA GENOMICS INC   (Taiwan)

Author keywords

Diabetic nephropathy; End stage renal disease; Single nucleotide polymorphisms; Type 2 diabetes

Indexed keywords

MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

EID: 77953447614     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005;20(12): 2587-2593.
2. Meguid El, Nahas A, Bello AK. Chronic kidney disease: The global challenge. Lancet. 2005;365(9456):331-340.
3. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346(15): 1145-1151.
4. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333-1346.
5. Hattersley AT, Pearson ER. Minireview: Pharmacogenetics and beyond: The interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology. 2006;147(6):2657-2663.
6. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2(6): 1306-1316.
7. de Borst MH, Benigni A, Remuzzi G. Primer: Strategies for identifying genes involved in renal disease. Nat Clin Pract Nephrol. 2008;4(5): 265-276.
8. Conway BR, Maxwell AP. Genetics of diabetic nephropathy: Are there clues to the understanding of common kidney diseases? Nephron Clin Pract. 2009;112(4):c213-c221.
9. Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN. Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet. 2000;67(5):1121-1128.
10. Even-Ram S, Yamada KM. Of mice and men: Relevance of cellular and molecular characterizations of myosin IIA to MYH9-related human disease. Cell Adh Migr. 2007;1(3):152-155.
11. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with non-diabetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185-1192.
12. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175-11784.
13. Freedman BI, Hicks PJ, Bostrom MA, et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009;75(7):736-745.
14. Freedman BI, Hicks PJ, Bostrom MA, et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant. 2009;24(11):3366-3371.
15. Freedman BI, Kopp JB, Winkler CA, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: The HyperGEN study. Am J Nephrol. 2009;29(6):626-632.
16. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPAR{gamma} and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009;24(11):3360-3366.
17. The International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-794.
18. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101(3):329-335.
19. D'Apolito M, Guarnieri V, Boncristiano M, Zelante L, Savoia A. Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes. Gene. 2002;286(2):215-222.
20. Marini M, Bruschi M, Pecci A, et al. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: Relevance for MYH9-related disease. Int J Mol Med. 2006;17(5): 729-736.
21. Singh N, Nainani N, Arora P, Venuto RC. CKD in MYH9-related disorders. Am J Kidney Dis. 2009;54(4):732-740.
22. Lin E, Hwang Y, Liang KH, Chen EY. Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics. 2007;8(1):75-83.
23. Lin E, Hwang Y, Chen EY. Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics. 2007;8(10):1327-1335.
24. Lin E, Hsu SY. A Bayesian approach to gene-gene and gene-environment interactions in chronic fatigue syndrome. Pharmacogenomics. 2009;10(1):35-42.
25. Lou XY, Chen GB, Yan L, et al. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet. 2007;80(6): 1125-1137.
26. Lin E, Hong CJ, Hwang JP, et al. Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression. Rejuvenation Res. 2009;12(6): 387-393.
27. Lin E, Pei D, Huang YJ, Hsieh CH, Wu LS. Gene-gene interactions among genetic variants from obesity candidate genes for nonobese and obese populations in type 2 diabetes. Genet Test Mol Biomarkers. 2009;13(4):485-493.
28. Lin E, Chen PS, Chang HH, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7): 1167-1172.
29. Lin E, Hwang Y, Wang SC, Gu ZJ, Chen EY. An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics. 2006;7(7):1017-1024.
30. Lin E, Huang LC. Identification of significant genes in genomics using Bayesian variable selection methods. Advances and Applications in Bioinformatics and Chemistry. 2008;1:13-18.
31. Lin E, Hwang Y. A support vector machine approach to assess drug efficacy of interferon and ribavirin combination therapy. Mol Diagn Ther. 2008;12(4):219-223.